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ABSTRACT  24 
Macrolide-resistant Mycoplasma pneumoniae (MRMP) is rapidly emerging in Asia but 25 
information on the temporal relationship between the increase in macrolide resistance and 26 
changes in strain types is scarce. Between 2011 and 2014, M. pneumoniae infection was 27 
diagnosed by PCR as part of routine care in a healthcare region in Hong Kong. Testing was 28 
initiated by clinicians, mainly in patients with suspected M. pneumoniae pneumonia. 29 
Specimens positive for M. pneumoniae were retrospectively investigated by macrolide 30 
resistance genotyping and a four loci (Mpn13-16) multilocus variable-number tandem-repeat 31 
analysis (MLVA) scheme. The overall percentage of M. pneumoniae-positive specimens was 32 
17.9% with annual rates ranging from 9.8%-27.2%. Prevalence of MRMP had rapidly 33 
increased from 13.6% in 2011, 30.7% in 2012, 36.6% in 2013 to 47.1% in 2014 (P = 0.038). 34 
Two major MLVA types 4-5-7-2 and 3-5-6-2 accounted for 75%-85% of the infections each 35 
year. MLVA types 4-5-7-2 and 3-5-6-2 predominated among macrolide-resistant and 36 
macrolide-sensitive groups, respectively. Increase in MRMP was mainly caused by 37 
increasing macrolide resistance in the prevalent MLVA type 4-5-7-2, changing from 25.0% 38 
in 2011, 59.1% in 2012, 89.7% in 2013 to 100% in 2014 (P < 0.001). In conclusion, 39 
increasing MRMP in Hong Kong was linked to a single MLVA type which was both 40 
prevalent and increasingly resistant to macrolides.   41 
 42 
  43 
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INTRODUCITON 44 
Mycoplasma pneumoniae (MP) is a common cause of community-acquired pneumonia and 45 
other respiratory tract infections (19). Community epidemics occur at intervals of 3 to 7 years. 46 
Infections develop in persons of all ages but it is primarily a disease of children and teenagers 47 
(2). When treatment is indicated, a macrolide is usually the drug of choice (2,19). However, 48 
macrolide-resistant M. pneumoniae (MRMP) have become increasingly prevalent worldwide 49 
and high rates (>80%) have been found in certain parts of the world (14,16,18,23). MRMP 50 
infections have been associated with persistence of symptoms, slower reduction in bacterial 51 
load, longer hospital stays, requirement for alternative therapy and higher frequency of 52 
complications (6,19,26). Strain typing is important for understanding changes in disease 53 
epidemiology and for investigation of outbreaks. In 2009, a multilocus variable-number 54 
tandem-repeat analysis (MLVA) scheme based upon five loci (Mpn1, Mpn13-16) was 55 
developed for the molecular typing of MP (8). It was initially used for investigation of 56 
isolates, but was later modified for directly typing MP in respiratory specimens (4,10,24). An 57 
amended 4 loci MLVA scheme was later proposed after studies had raised concerns on the 58 
instability of the Mpn1 locus (1,21). In clinical laboratories, culture and characterization of 59 
MP is seldom performed. Therefore, MP typing was usually carried out on isolates collected 60 
from sporadic cases and outbreaks (1,8,9), limiting the inferences that can be made about 61 
trends in MP infections. In addition, information on the temporal relationship between the 62 
increase in macrolide resistance and changes in strain types is scarce (9). Here, MLVA 63 
analysis was used to investigate the MP strain type and macrolide resistance genotype in 64 
respiratory specimens collected consecutively from patients in a healthcare region in Hong 65 
Kong over a 4-year period.   66 
 67 
 68 
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MATERIALS AND METHODS 69 
Study design. This retrospective study was conducted in a healthcare region in Hong Kong 70 
comprising one university-affiliated hospital with 1600 beds, three extended-care hospitals 71 
with a total of 1600 beds, and one paediatric hospital with 160 beds. Diagnostic PCR assay 72 
for MP was provided as a routine service for inpatients by a clinical microbiology laboratory 73 
(5,6). Testing was initiated by clinicians, mainly in patients with features suspicious of MP 74 
pneumonia (2,15). Nasopharyngeal aspirate was collected in viral transport medium (7). 75 
Sputum and other respiratory specimens were collected using standard techniques (5). 76 
Patients were included if their respiratory specimens were obtained for MP testing by PCR 77 
between January 2011 and December 2014. During the study period, a total of 1657 78 
respiratory specimens from 1433 patients were investigated by real-time PCR test for the 79 
presence of MP. Overall, 257 (17.9%) patients, including 274 (16.5%) specimens were 80 
positive for MP. The 274 MP-positive specimens comprised 264 nasopharyngeal 81 
aspirates/swabs, five pleural specimens and five other respiratory specimens (sputum, 82 
bronchial aspirate). The data was analysed by five age groups: 0-1 year (infants, n = 11), 2-83 
11 years (children, n = 195), 12-17 years (teenagers, n = 33), 18-64 years (adults, n = 16), 84 
≥65 years (seniors, n = 2). The patients were diagnosed with pneumonia (n = 231), upper 85 
respiratory tract infection (n = 7), non-specific respiratory illness (n = 9) and acute 86 
bronchiolitis (n = 1). In nine patients, no information on the syndromic diagnosis was 87 
available. Clinical features and macrolide resistance genotyping results for 101 of the patients 88 
have been reported previously (5,6). Nucleic acid extracts from the 257 patients with positive 89 
MP results were retrospectively retrieved for further testing. Only one specimen from each 90 
patient was included. 91 
 92 
5 
 
Nucleic acid extraction. Nucleic acid extraction was performed by using the NucliSENS 93 
easyMAG extraction system (bioMérieux, France) and stored at -80 oC, as described 94 
previously (5). All testing was performed on nucleic acid extracted from the clinical 95 
specimens. Culture for MP was not performed. 96 
 97 
Real-time qPCR for the detection of M. pneumoniae. Real-time quantitative (qPCR) was 98 
conducted for the detection of MP using TaqMan universal PCR master mix (Applied 99 
Biosystems) in a StepOnePlus instrument (Applied Biosystems, Foster City, CA), as 100 
previously described (5). A series of 6 log10 dilutions equivalent to ten to 1 × 106 copies per 101 
reaction mixture were prepared from a plasmid (pC-RII-TOPO vector; Invitrogen, CA) 102 
containing the corresponding target bacterial sequence to generate calibration curves; these 103 
were ran in parallel with the test specimens. The detection limit of the qPCR assay was 104 
approximately ten copies per reaction mixture (5). 105 
 106 
MRMP genotype detection. SimpleProbe real-time PCR coupled to melting curve analysis 107 
(SimpleProbe PCR) was performed on the extracted nucleic acid from specimens to identify 108 
MRMP. The MRMP assay was done by using the LightCycler FastStart DNA master 109 
HybProbe kit (Roche Diagnostics, Germany) according to a published protocol (5). The 110 
detection limit of SimpleProbe PCR for both wild-type and mutant was 103 copies per 111 
reaction. A randomly chosen subset of the specimens was subjected to Sanger sequencing for 112 
confirmation.  113 
 114 
MLVA typing. Previously published primers were used to amplify four variable-number 115 
tandem-repeat (VNTR) loci (Mpn13-16) (24). Our initial testing showed that nonspecific 116 
bands were commonly observed if all loci were amplified together in one multiplex reaction. 117 
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After optimization, good results were obtained through amplification of the loci in two 118 
duplex reactions, one for Mpn13 and Mpn15, and one for Mpn14 and Mpn16.  The PCR was 119 
performed using 2 μl nucleic acid, 15 μl 2 × QIAGEN multiplex master mixes (QIAGEN), 120 
concentrations for each primers were 0.2 μM for Mpn13 and Mpn15, 0.4 μM for Mpn14 and 121 
0.08 μM for Mpn16. The total reaction mixture volume was made up to 30 μl with nuclease-122 
free water. A Veriti 96-well thermal cycler (Applied Biosystems) was used for amplification. 123 
Cycling conditions were as follows: denaturation step of 15 min at 95 °C, amplification step 124 
of 40 cycles of 30 s at 95 °C, 30 s at 62 °C, and 45 s at 72 °C. The products were then pooled 125 
into one tube for product size determination in one lane by capillary electrophoresis using an 126 
ABI 3130 genetic analyser (Applied Biosystem), and the data was analysed using 127 
GeneMapper software (version 4.0, Applied Biosystems).  The primers were fluorescently 128 
labelled at the 5’ end with VIC (green, Mpn13 and Mpn15), NED (yellow, Mpn14) or 6-129 
FAM (blue, Mpn16) (Applied Biosystem). The fluorescent labels for the targets together with 130 
the expected product sizes of each locus allowed sizing of the amplicons for all four loci in 131 
one reaction mixture. The number of repeats for each locus was calculated according to the 132 
PCR fragment size. The MLVA type was designated by the numeric combination of the 133 
number of tandem repeats at four loci (Mpn13-16), as suggested previously (1,9). The 134 
number of repeats was rounded up to an integer value (8,24). The number of repeats in each 135 
locus (1 to 2 specimens for each product size) was confirmed by Sanger sequencing. 136 
 137 
Statistical analysis. Statistical analysis was performed using SPSS Statistics version 23 for 138 
Windows. Chi-square tests were used to compare categorical variables. A P value of < 0.05 139 
was considered statistically significant. 140 
  141 
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 142 
RESULTS 143 
Prevalence of M. pneumoniae. The percentage of test-positive patients per month from 2011 144 
to 2014 is shown in Fig 1. Higher positive rates (more than 1 standard deviation above 145 
average for the entire period) were observed in 2012 (April, June, July, September) and 2013 146 
(May to July). The percentage of test-positive patients by year was 9.8% in 2011, 27.2% in 147 
2012, 24.3% in 2013 and 11.4% in 2014 (P < 0.001). 148 
The MP-positive rate was highest among children aged 2-11 years (33.2%) and 149 
teenagers aged 12-17 years (30.6%), then in infants aged 0 to 1 year (7.6%); it was lowest in 150 
adults aged 18 to 64 years (4.0%) and seniors aged 65 years (1.0%) (P < 0.001). The positive 151 
rate was higher in females than in males (21.8% versus 14.5%, P < 0.001). 152 
 153 
Prevalence of macrolide-resistant genotype. The MP-positive specimens for 16 patients 154 
were of an insufficient amount and not investigated further. Macrolide-resistant genotyping 155 
could be successfully carried out on all specimens from the remaining 241 patients. 156 
SimpleProbe real-time PCR coupled to melting curve analysis identified 34.9% (84/241) of 157 
the unique patient specimens as MRMP genotype. The A2063G transition was the only 158 
mutation identified. A subset of 88 specimens, including 61 with MSMP genotype and 27 159 
with MRMP genotype was further analysed by Sanger sequencing. The results were 100% 160 
concordant with melting curve analysis. The annual prevalence of MRMP among all MP-161 
positive patients had significantly increased from 13.6% (3/22) in 2011 to 30.7% (23/75) in 162 
2012, 36.6% (34/93) in 2013 and 47.1% (24/51) in 2014 (P = 0.038). The prevalence of 163 
MRMP genotype was higher among children (aged 0-1 years, 30.0%; aged 2-11 years, 36.1%; 164 
aged 12-17 years, 39.7%) than in adults (aged 18-64 years, 20.0%, aged ≥65 years, 0%) but 165 
8 
 
the difference was not statistically significant (P = 0.122). MRMP prevalence among males 166 
(33.7%) and females (35.7%) were similar (P = 0.742).  167 
 168 
Temporal changes in macrolide resistance rate and MLVA types. Specimens from the 169 
241 patients with sufficient DNA extracts were further investigated by MLVA typing and 170 
successful results were obtained for 205 (85.1%) patients. The number of repeats in the four 171 
loci were 3 to 5 for Mpn13, 4 to 6 for Mpn14, 6 to 7 for Mpn15 and 2 to 3 for Mpn16, giving 172 
seven distinct MLVA types. The major types were 3-5-6-2 (44.4%), 4-5-7-2 (36.6%) and 4-5-173 
7-3 (14.1%). Other rare types, including 3-6-6-2 (n = 4), 5-5-7-2 (n = 3), 4-6-7-3 (n = 2) and 174 
4-4-7-3 (n = 1) only accounted for 4.9% of the total.  175 
During the four year period, types 4-5-7-2 and 3-5-6-2 were predominant (Fig. 2). 176 
Together the two types comprised 75% to 85% of all positive specimens in each year. The 177 
proportion of type 4-5-7-2 had an increasing trend from 29% in 2011, 34% in 2012, 36% in 178 
2013 and 43% in 2014 but the difference was not statistically significant (P = 0.686). Of the 179 
seven MLVA types, five and four MLVA types were found among specimens with 180 
macrolide-sensitive M. pneumoniae (MSMP) and MRMP genotypes, respectively (Fig. 3A). 181 
The two major MLVA types (3-5-6-2 and 4-5-7-2) occurred in the MRMP and MSMP groups 182 
at different frequencies. The prevalence of MLVA type 4-5-7-2 was substantially higher in 183 
the MRMP group than in the MSMP group (89.6% versus 10.9%, P < 0.001). In contrast, 184 
MLVA type 3-5-6-2 was more prevalent in the MSMP group than in the MRMP group 185 
(64.5% vs. 3.0%, P < 0.001). The other five MLVA types were found at low frequencies in 186 
either the MRMP group (5-5-7-2 and 4-6-7-3) or the MSMP group (4-5-7-3, 4-4-7-3 and M3-187 
6-6-2) only. Stratification by year revealed that macrolide resistance rate of MLVA type 4-5-188 
7-2 had significantly increased from 25.0% in 2011 to 100% in 2014 (Fig. 3B, P < 0.001).  189 
 190 
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DISCUSSION 191 
In this study, an increase in the rate of MP infection was noted in 2012 and 2013, suggesting 192 
that there was an epidemic outbreak during this period. During the entire period, changes in 193 
the annual cycle of positive rates were irregular, with peaks in early summer (in 2012), mid-194 
summer (in 2013) or early autumn (in 2014). This is in line with reports describing more MP 195 
infections with increased relative humidity and ambient temperature (17,22). In our 196 
neighborhood areas, recent epidemic outbreaks of MP infections were also noted in South 197 
Korea from 2010-2011, in Japan from 2011 to 2012 and in Beijing and Shanghai, China in 198 
2012 (13,16,20). Notably, a substantial increase in the prevalence of MRMP was noted in the 199 
areas during or shortly after those epidemics (12-14,16,20). Our data revealed that the MRMP 200 
rate had increased by more than three folds from 13.6% in 2011 to 47.1% in 2014. Reported 201 
rates of MRMP range from 62.9% in South Korea (12) and >80% to 90% in China and Japan 202 
(14,26), compared to ≤10% in Europe and the United States (9,19). The relationship between 203 
MP epidemics and MRMP emergence is likely to be complex, involving selection pressure 204 
from widespread administration of macrolides (12).  205 
Two MLVA types (3-5-6-2, 44.4% and 4-5-7-2, 36.6%) accounted for 81.0% of the 206 
infections during the study period. Both types occur worldwide and were among the 207 
predominant types in many studies. Amongst international collections of MP isolates 208 
collected over decades, 14.0%-20.8% and 50.6%-55.1% were of MLVA types 3-5-6-2 and 4-209 
5-7-2, respectively (1,8). During the periods with a high proportion of MP-positive specimens, 210 
the major genotypes did not change (Figure 2A). This suggests that increased detection of 211 
MP infections is likely a result of increased transmission of co-circulating MLVA types, 212 
rather than introduction of new types to the community.  213 
This study found that increase in MRMP was predominantly a result of increasing 214 
resistance in MLVA type 4-5-7-2. Macrolide resistance rate of this type had drastically 215 
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increased from 25% in 2011 to 100% in 2014. All the other MLVA types including the 216 
prevalent 3-5-6-2 type remained largely macrolide-sensitive. Qu et al previously reported the 217 
same significant correlation between macrolide resistance and susceptibility with type 4-5-7-218 
2 and type 3-5-6-2, respectively (20). In the two international MP collections described by 219 
Degrange et al and Benitez et al, four (33.3%) of 12 and nine (90%) of ten MRMP isolates 220 
were of MLVA type 4-5-7-2, respectively (1,8). In the United States, 13 (68.4%) of 19 221 
MRMP isolates identified through CDC-assisted investigations across the country between 222 
2006 and 2013 belonged to MLVA type 4-5-7-2 (9). In China, this MLVA type accounted for 223 
>90% of the MRMP isolates identified in Beijing from 2010 to 2013 (20,24,25). Of the 21 224 
distinct types that could be distinguished by the amended four loci MLVA scheme (1,3,4,8-225 
11,18,20,21,23-25) (Table S1, supplementary file), MRMP has been detected in 12 types. 226 
Among the published reports, prevalence of the other 11 types among MRMP were low and 227 
occurrence was sporadic (1,8,9,11,18,20,21,23-25).   228 
As far as we know, this is the first report to demonstrate a link between changes in 229 
MRMP prevalence and increasing resistance within a single MLVA type. Inclusion of 230 
consecutive specimens from a 4-year period and a relatively large sample size are the 231 
strengths of this study. Given that this retrospective analysis only examined specimens from 232 
inpatients of whom the majority were diagnosed with pneumonia, the findings may not be 233 
representative of mild MP infections in the community. MP is a genetically conserved 234 
organism. Pairwise comparison of the four published MP genomes (strains M29, M129, 309 235 
and FH) revealed that the difference between strains of different MLVA types (4-5-7-2 236 
versus 3-5-6-2) was 0.3%-0.5% while difference between strains of the same MLVA types 237 
was 0.08% (Table S2, supplementary file). Therefore, whole genome sequencing may be the 238 
ultimate approach for resolving whether there is any MRMP subclone within type 4-5-7-2.  239 
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 In summary, we demonstrated a link between increasing macrolide resistance and the 240 
expansion of MRMP strains of the MLVA type 4-5-7-2 in Hong Kong during 2011-2014. It 241 
is worrying that type 4-5-7-2 may be associated with more severe disease (20). Increasing 242 
public awareness, enhancing access to rapid diagnostics and improving surveillance for MP 243 
and macrolide resistance is necessary to inform case and outbreak management and to 244 
understand the burden of disease.   245 
 246 
 247 
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FIG 1. M. pneumoniae positive rate in respiratory specimens by date of request for a 255 
healthcare region in Hong Kong, January 2011-December 2014. Histogram shows the 256 
monthly number of specimens tested. Dotted line shows the percentage of specimens positive 257 
for MP in each month. Horizontal line showed the average positive percentage for the entire 258 
period. Only one specimen per patient was included. 259 
 260 
 261 
FIG 2. MLVA type in M. pneumoniae specimens in a healthcare region in Hong Kong, 2011-262 
2014. The percentage of each MLVA type for each year is shown. The number of patients in 263 
each year is shown within parentheses.  264 
 265 
 266 
FIG 3. Macrolide resistance in M. pneumoniae specimens in a healthcare region in Hong 267 
Kong, 2011-2014. (A) MLVA type according to macrolide resistance genotype. The 268 
proportions of MLVA types for MRMP (n = 67) and MSMP (n = 138) groups are shown in 269 
the outer and inner doughnuts, respectively. Others in the MRMP group included types 4-6-7-270 
3 and 5-5-7-2. Others in the MSMP group included types 3-6-6-2 and 4-4-7-3. (B) Changes 271 
in macrolide resistance rate of MLVA type 4-5-7-2 during 2011-2014. The number of 272 
patients in each year is shown within parentheses.  273 
 274 
 275 
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